CD185 (CXCR5) Monoclonal Antibody (MU5UBEE), PE-Cyanine5, eBioscience™, Invitrogen™

Description

• The BMA12 monoclonal antibody reacts with mouse CD100, also known as Sema4D
• Sema4D/CD100 is a 150kDa transmembrane protein expressed constitutively on T cells and is involved in the activation of B cells through its interaction with CD72
• Interaction of these two proteins diminishes the negative signaling normally effected by CD72
• CD100 is already expressed strongly on resting T cells and somewhat weakly on B cells, but activation upregulates expression on both cell types
• Antigen expression has been reported in Spleen, thymus and l CXCR5 (C-X-Chemokine Receptor Type 5, CD185) also known as Burkitt lymphoma receptor 1 (BLR1) belongs to the CXC chemokine receptor family
• CXCR5 is a G protein-coupled seven transmembrane receptor for chemokine BLC
• CXCR5 gene is specifically expressed in Burkitt's lymphoma and lymphatic tissues, such as follicles in lymph nodes, as well as in spleen
• Studies of CXCR5 suggest that it plays an essential role in B cell migration
• CXCR5 expression has been reported in human blood and salivary gland and in animal lymphatic organs, blood, bone marrow, brain, liver, lymph node, skin, spleen, stomach, and tonsil
• ESTs (expressed sequence tags) have been isolated from human brain, germ cell, lung, lymph, and pancreas
• G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
• All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
• An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
• Research studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
• This &quoteturn-off&quote activity in GPCRs have tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
• Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which are used in mental health and allergy applications, respectively.